Organisation paid for research Program year 2025 Source: CMS Open Payments

Vida Clinical Studies LLC

Neither a doctor nor a teaching hospital

Research payments

$207,789

49 payments

Through program year 2025, Vida Clinical Studies LLC is reported as receiving $207,789 in research payments, across 49 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$35,500	6
2023	Research	$60,731	2
2021	Research	$16,255	13
2020	Research	$15,640	12
2019	Research	$79,664	16

Breakdown

Who paid Research payments · program years 2019–2025

Allergan Inc. $111,558 41 payments
GlaxoSmithKline, LLC. $60,731 2 payments
Merz Pharmaceuticals, LLC $35,500 6 payments

Studies the money was for Research payments · program years 2019–2025

A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $65,108 12 payments
A Phase 1/2, Randomized, Dose-Finding/Dose-Confirmation Study to Evalu $60,731 2 payments
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Chronic Migraine $17,750 3 payments
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin Injections for Preventing Episodic Migraine $17,750 3 payments
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis $11,705 5 payments
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) $9,690 8 payments
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure $8,800 3 payments
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $7,014 5 payments
46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) $4,801 4 payments
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis $4,440 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.